ReviewCurrent oncology reports2026
The Influence of GLP-1 Receptor Agonists on the Outcomes and Tolerability of Colorectal Cancer Therapies.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewGlucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly being prescribed for metabolic diseases. At times, patients taking GLP-1RAs are also undergoing cancer treatment and surgeries, but their potential interactions with cancer therapies are not well delineated. The purpose of this narrative review is to synthesize the limited pre-clinical, translational, and the clinical evidence available, examining the biological rationale and mechanisms for GLP-1RA-cancer therapy interactions. RECENT
findingsOncology research on GLP-1RAs has primarily focused on cancer incidence and survival, yielding generally reassuring safety data and potential outcome improvements. While emerging evidence and biological studies suggest GLP-1RAs could influence treatment tolerance and toxicity, the current clinical data remains limited, observational, and poorly integrated. However, there has been decent mechanistic research that suggests biologically plausible interactions of GLP1-RAs and cancer therapies, specifically through the AMPK and mTOR pathways. The available clinical evidence suggests that GLP-1 receptor agonist use is associated withimproved survival outcomes and reduced treatment-related complications among patients with colorectalcancer receiving chemotherapy, immunotherapy, or surgery. However, these findings are mostlyobservational, and conflicting preclinical evidence highlights the need for prospective studies to clarifythe underlying mechanisms, establish causality, and determine the clinical implications of theseinteractions.
Indexed as
Identifiers
42983002What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.